AFFY
Affymax, Inc.
Set alert
0.00 USD 0.00 0.00%
0.0009 Day range 0.0009
0.0007 52-week range 0.0416
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0009
- Prev close
- 0.0008
- Mkt cap
- 29.99K
- Vol
- 6.00K
- Avg vol
- 1.17K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0009
- High
- 0.0009
- Forward P/E
- 0.00
- Beta
- 2.14
- Short ratio
- 2.35
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Nov 27, 2014
- Earnings
- May 6, 2014
- 50-d avg
- 0.074286
- 200-d avg
- 0.073304
- 1y target
- 1.00
Key statistics
- Market cap
- 2.55M
- Enterprise value
- -774.69K
- Trailing P/E
- 0.83
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 60.70
- Price / book
- 0.49
- EPS (TTM)
- 0.082
- Beta
- 2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 7300.00%
- Revenue (TTM)
- 42.00K
- Revenue growth
- -92.00%
- Free cash flow
- -41.41M
- Total cash
- 3.40M
- Total debt
- 0
- Return on equity
- 111.59%
- Shares outstanding
- 37.49M
- Short % of float
- 49.35%
- 50-day average
- 0.074286
- 200-day average
- 0.073304
Analyst view
Consensus: hold
Hold
Price target (mean) 1.00
Next earnings
May 6, 2014
Expected May 6, 2014. Consensus EPS estimate 0.00.
Financials — quick view
AFFY Revenue — quarterly 42.00K
AFFY Net income — quarterly 7.21M
AFFY EPS — quarterly 0.19
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2014 | Mar 1, 2014 | 0.00 | — | — | — |
| Mar 31, 2014 | Dec 1, 2013 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 2013 | WBB Securities | down | Buy | Hold |
| Mar 18, 2013 | MLV & Co | down | Hold | Sell |
| Feb 24, 2013 | Stifel Nicolaus | down | Buy | Hold |
| Feb 24, 2013 | Robert W. Baird | down | Outperform | Neutral |
| Feb 24, 2013 | MLV & Co | down | Buy | Hold |
| May 7, 2012 | WBB Securities | down | Strong Buy | Buy |
About Affymax, Inc.
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- affymax.com
News
Your note
Sign in to keep a note on AFFY — it syncs with the Stock Master app.